Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05606965 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults
A Phase 2 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
NCT05606965 is a Phase 2 study that has completed, run by ModernaTX. The registered enrollment target is 172 participants.
The verdict
NCT05606965, a Phase 2 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
Study Summary
The main purpose of the study is to evaluate the safety, reactogenicity, and the humoral immunogenicity of mRNA-1010 and comparator influenza vaccines against homologous influenza A and B strains at Day 29.
Interventions
- BIOLOGICAL Inactivated Influenza Vaccine
- BIOLOGICAL mRNA-1345
- BIOLOGICAL mRNA-1010
- BIOLOGICAL Egg-based Quadrivalent Influenza Vaccine
- BIOLOGICAL Adjuvanted Quadrivalent Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2022-11-02 |
| Est. Completion | 2025-11-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05606965
The ClinicalTrials.gov registry entry for NCT05606965 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Inactivated Influenza Vaccine is the first listed.
NCT05606965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05606965 about?
NCT05606965 is a clinical study titled "A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults". The main purpose of the study is to evaluate the safety, reactogenicity, and the humoral immunogenicity of mRNA-1010 and comparator influenza vaccines against homologous influenza A and B strains at Day 29.
What is the current status of trial NCT05606965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2022-11-02. Estimated completion is 2025-11-13.
What interventions are being tested in trial NCT05606965?
The interventions under investigation include: Inactivated Influenza Vaccine (BIOLOGICAL), mRNA-1345 (BIOLOGICAL), mRNA-1010 (BIOLOGICAL), Egg-based Quadrivalent Influenza Vaccine (BIOLOGICAL), Adjuvanted Quadrivalent Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05606965?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.